

BIOSIMILAR INITIATIVE EXCEPTION SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

PATIENT INFORMATION					<u> </u>	COVERAGE T	YPE
PATIENT LAST NAME	FIRST NAME				INITIAL	☐ Alberta Blue Cross ☐ Alberta Human Services	
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUM			MBER		Other	
STREET ADDRESS	CITY			PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER	
NOTIFICATION						_	
You may be eligible to receive the requested drug benefits. Infor (A) for your prescriber to release necessary and relevant information Alberta Blue Cross to release that to Alberta Health and the rusage information may be released to Alberta Health.	ition to Alberta Blue Ci	ross, to Alberta	a Health, to A	Alberta Hu	man Services (if re	quested) for the Biosir	milar Initiative Exception; and (B)
PATIENT CONSENT							
I hereby authorize: (A) my prescriber to release to Alberta Blue C specialists who review the request, the information on this form recipients collecting such information.							
Date (YYYY-MM-DD) Patient's signature							
PRESCRIBER INFORMATION							
PRESCRIBER LAST NAME FIRST NAME INITIA			PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION				TRATION
STREET ADDRESS			CPSA ACO CARNA ACO ACP Other		ON NUMBER		
CITY, PROVINCE			PHONE		FAX	FAX	
POSTAL CODE		FAX NUMBER MUST BE PROVID			/IDED WITH EACH	DED WITH EACH REQUEST SUBMITTED	
Indicate requested originator drug where b	osimilar	Diagnosi	is (please	e speci	fy)		Dosage
cannot be used							
Please specify requested originator			icade an weight (k	Frequency			
			For Rituxan requests for GPA/MPA only: Body surface area (m²)				
Please provide additional documentation for	r the following	in order f	or the ex	ceptio	n request to	be considered:	
1. Please provide summary of clinical status and disease course: Please include ALL applicable clinical assessment scores							
2. Please provide previous / current medications used: Please indicate when the medications were used, dose, duration of use and response to each treatment							
3. Please provide rationale for Exception Request: Clearly indicate the reason(s) why patient is unable to switch to the biosimilar							
4. Please provide information as to whether the patient has tried the biosimilar(s):							
 a) If so, please provide the duration if applicable, laboratory values (e. frequency and severity of adverse A1c change while on biosimilar ve 	g. A1c changes eeffects (e.g. for	for insulin insulin gla	glargine	while o	n biosimilar), (detailed docume	entation to include
 b) If not, please provide additional clean intestinal resections, include any co-morbidities are well controlled 	underlying, diagr	nosed co-r	o patient' norbiditie	s condi s that p	ition (e.g. for (preclude use c	Crohn's, the nun f the biosimilar,	nber and date of any and indicate if such
If the reason for exception request is pregnand	y, indicate if pat	ient is curr	ently pre	gnant	Yes, antici	oated due date	□No
PRESCRIBER'S SIGNATURE DATE ONCE YOUR REQUEST HAS SUCCESSED LYTE		, ,	10009 108 9 FAX 780- 4	e Cross, Street NV 498-83	Clinical Drug Se V, Edmonton, All 84 in Edmonton •	perta T5J 3C5 1-877-828-4100	5 toll free all other areas